Skip to main content
. 2018 Oct 16;11:7031–7040. doi: 10.2147/OTT.S179730

Figure 1.

Figure 1

Brevilin A decreased cell viability of glioblastoma cells.

Notes: (A) Chemical structure and HPLC purity peak of Brevilin A. (B) U87, (C) U373, and (D) LN229 glioblastoma cells were treated with Brevilin A in a dose-dependent manner for 24 hours. Temozolomide was used as the positive control. The cell viability was determined as described in Materials and methods. Data are expressed as mean ± SEM of three independent experiments. Columns with different superscript letters showed statistically significant differences (P<0.05).